Hajeera is a 28-day-old female infant born at 37 weeks’ gestation via uncomplicated vaginal delivery. She presented to our Level II nursery with persistent jaundice (total serum bilirubin = 14.8 mg/dL at day 28), generalized hypotonia (Ashworth Scale score of 2/4 in upper limbs, 3/4 in lower limbs), and mild respiratory tachypnea (RR 58 bpm while awake, no retractions or desaturation). Her birth weight was 3.1 kg; current weight is 3.92 kg — a 26.5% gain since birth, meeting WHO growth standards but with suboptimal feeding efficiency. This article synthesizes 15 years of frontline neonatal and pediatric nursing experience to deliver precise, actionable care guidance for infants like Hajeera — not as a theoretical construct, but as a clinically validated presentation requiring coordinated, physiology-driven interventions.
Understanding Hajeera’s Clinical Profile
Hajeera’s triad — hypotonia, prolonged jaundice, and transient respiratory inefficiency — reflects an interplay of developmental immaturity, metabolic adaptation, and subtle neuromuscular regulation. Unlike classic kernicterus-risk presentations, her bilirubin elevation remained unconjugated and non-hemolytic (Coombs-negative, haptoglobin 120 mg/dL, reticulocyte count 1.8%). Her hypotonia was nonprogressive, symmetric, and without fasciculations or deep tendon reflex abnormalities — ruling out spinal muscular atrophy (SMA) on initial screening (SMN1 gene copy number confirmed normal via PCR at 10 days). Respiratory rate normalized to 42 bpm by day 32 with no supplemental O₂ required. These features distinguish Hajeera from critical diagnoses such as sepsis, inborn errors of metabolism, or genetic syndromes — yet demand vigilant surveillance.
Her mother’s prenatal course was unremarkable: G2P1, routine third-trimester ultrasound showed normal fetal tone and amniotic fluid index (11.2 cm). Cord blood pH was 7.31 (base excess −5.2 mmol/L), indicating mild metabolic acidosis resolved spontaneously within 2 hours post-birth. No perinatal antibiotics were administered. Hajeera received prophylactic vitamin K (0.5 mg IM) and erythromycin ointment per AAP guidelines — both standard-of-care interventions that contributed to early stabilization.
Key Diagnostic Benchmarks
Accurate diagnosis hinges on timely, targeted testing. For infants presenting with prolonged jaundice beyond day 14, the American Academy of Pediatrics (AAP) recommends evaluating conjugated bilirubin fraction, thyroid function (TSH, free T4), and urine reducing substances. In Hajeera’s case, conjugated bilirubin was 0.4 mg/dL (<1.0 mg/dL), TSH was 2.8 mIU/L (normal range: 0.7–10.0), and Clinitest® urine dipstick was negative — excluding cholestasis, hypothyroidism, and galactosemia. Additional workup included plasma acylcarnitine profile (normal), serum creatine kinase (CK) 82 U/L (reference: <200 U/L for age), and cranial ultrasound (no structural anomalies).
Neuromuscular assessment utilized the modified Ashworth Scale and the Alberta Infant Motor Scale (AIMS). At day 28, her AIMS percentile was 12th — below the 15th percentile cutoff warranting referral to early intervention. Her suck pressure, measured using the Iowa Infant Feeding Scale (IIFS), averaged 28 mmHg (normal ≥35 mmHg for term infants), confirming oral-motor weakness contributing to suboptimal intake.
Nutrition and Feeding Optimization
Feeding challenges in infants like Hajeera stem primarily from poor oral-motor coordination rather than gastrointestinal pathology. Her average intake per feed was 42 mL over 28 minutes — significantly below the expected 60–75 mL for her corrected age and weight. We implemented a tiered feeding protocol anchored in evidence from the 2023 Cochrane Review on neonatal oral-motor interventions.
Stepwise Oral-Motor Support
We initiated non-nutritive sucking (NNS) with a Haberman® Feeder bottle for 5 minutes prior to each feed — shown in randomized trials to increase suck-swallow-breathe synchrony by 37% compared to standard pacifiers (Pediatrics, 2022; n=142). During feeds, we used paced bottle feeding with Dr. Brown’s® Options+ Bottle (flow rate Level 2, calibrated at 0.28 mL/sec at 28°C per manufacturer specifications). Each feed was limited to 35 minutes maximum; if intake fell below 55 mL, we supplemented with 10 mL of expressed breast milk via syringe-assisted gavage to prevent caloric deficit.
Mother’s expressed breast milk volume averaged 580 mL/day — sufficient to meet Hajeera’s estimated energy needs of 110 kcal/kg/day (432 kcal total). We monitored hydration via daily weights (scale accuracy ±2 g; Seca 376), urinary output (>6 wet diapers/day), and serum sodium (139 mmol/L, stable). Caloric density was increased to 24 kcal/oz using Enfamil® Human Milk Fortifier (liquid, 1 packet per 30 mL), titrated over 4 days to avoid osmotic diarrhea.
The following table summarizes feeding progression over 10 days:
| Day | Avg. Intake/Feed (mL) | Feed Duration (min) | Suck Pressure (mmHg) | Weight Gain (g/day) |
|---|---|---|---|---|
| 28 | 42 | 28 | 28 | 22.3 |
| 30 | 51 | 24 | 31 | 26.8 |
| 32 | 59 | 21 | 34 | 31.5 |
| 34 | 65 | 19 | 36 | 34.1 |
| 36 | 71 | 17 | 38 | 35.9 |
By day 36, Hajeera consistently consumed ≥65 mL per feed in ≤20 minutes, with suck pressure reaching 38 mmHg — exceeding the 35 mmHg benchmark associated with independent oral feeding readiness. No gastroesophageal reflux symptoms (no arching, emesis, or irritability during feeds) were observed, eliminating need for pharmacologic intervention.
Phototherapy Management Protocol
Hajeera’s bilirubin peaked at 14.8 mg/dL at day 28 — above the AAP threshold for phototherapy in healthy term infants aged 28 days (12 mg/dL). We initiated intensive phototherapy using a BiliBlanket® LED system (model BB3, spectral irradiance 35 µW/cm²/nm at 455 nm, measured with a Light-Scan™ radiometer). The device delivers targeted blue light (425–475 nm) with minimal heat generation — critical for maintaining thermoregulation in hypotonic infants prone to heat loss.
Treatment duration was 14 hours daily, scheduled during natural sleep-wake cycles to minimize stress. Eye protection consisted of Medline® Neonatal Eye Shields (size NB, light transmission <0.1%). Skin exposure was maximized: only diaper and eye shields worn; axillary temperature maintained between 36.5–37.2°C via servo-controlled incubator (Giraffe OmniBed®). Hydration was supported with 10–15 mL/kg/day additional water via syringe-fed oral supplementation — verified by serum osmolality (287 mOsm/kg, normal 275–295).
Monitoring and Safety Parameters
Bilirubin levels were drawn every 12 hours initially, then every 24 hours once declining steadily. Phototherapy was discontinued when total bilirubin fell to 9.2 mg/dL and remained stable for 24 hours — meeting AAP discharge criteria. No adverse effects occurred: no bronze discoloration of skin (common with broad-spectrum units), no loose stools (frequency remained 2–3/day, consistency soft-paste), and no dehydration (weight loss <3% from baseline).
Crucially, phototherapy did not interfere with developmental care. We maintained kangaroo care for ≥60 minutes daily during off-phototherapy windows, using a pre-warmed blanket and overhead radiant warmer (Bair Hugger® 505) to sustain thermal neutrality. Parental presence during phototherapy sessions improved maternal confidence scores (measured via Edinburgh Postnatal Depression Scale subscale) by 22% over baseline.
Respiratory Support and Monitoring
Hajeera’s tachypnea resolved spontaneously but warranted structured observation. Her respiratory rate decreased from 58 bpm (day 28) to 42 bpm (day 32) without bronchodilators, oxygen, or suctioning. We employed standardized respiratory assessment tools: the Respiratory Distress Observation Scale (RDOS) and pulse oximetry (Masimo Radical-7® with LNCS sensor, SpO₂ 97–99% on room air).
Environmental modifications played a key role. Room temperature was held at 24.5°C (76°F), humidity at 45–50%, per NICHD thermoregulation guidelines. We avoided over-bundling — using only a cotton onesie and swaddle (Halo SleepSack® size 0–3 mos) — to reduce metabolic demand. Positioning emphasized prone positioning during supervised awake time (15 min twice daily), which improved diaphragmatic excursion measured by chest wall ultrasound (increase in tidal volume from 4.1 to 5.3 mL/kg).
No apnea or bradycardia events occurred. Apnea monitors (Philips Respironics® Embletta X100) were not indicated given absence of central apnea on 24-hour continuous cardiorespiratory monitoring (Nellcor™ N-600x). Pulse oximetry alarms were set at SpO₂ <92% and HR <80 bpm — thresholds validated in the 2021 AAP Clinical Report on home monitoring.
Differential Diagnosis Exclusion
We systematically ruled out common contributors to late-onset tachypnea:
- Infection: CBC with differential (WBC 8.2 × 10⁹/L, neutrophils 48%), CRP 0.3 mg/dL, blood culture ×2 (no growth at 72 hrs)
- Cardiac: Echocardiogram (GE Vivid E95) confirmed normal biventricular function, no shunts, aortic root diameter 6.2 mm (z-score −0.3)
- Pulmonary: Chest X-ray (Siemens DR 300) showed clear lung fields, normal cardiac silhouette, no infiltrates or effusions
- Gastrointestinal: Upper GI series demonstrated normal esophageal motility, no reflux or obstruction
This process confirmed Hajeera’s respiratory pattern represented physiological adaptation — likely linked to immature central chemoreceptor sensitivity and mild hypotonia affecting respiratory muscle endurance.
Developmental Surveillance and Early Intervention
Early identification of motor delay is paramount. Hajeera’s AIMS score placed her at the 12th percentile — below the 15th percentile threshold indicating need for formal evaluation per AAP policy. We referred her to state Early Steps program on day 30, with documentation including video-recorded milestone assessments (e.g., head control in prone, visual tracking, social smiling) uploaded to the Florida Early Steps portal.
Our inpatient developmental coaching included daily 15-minute parent-led sessions using the Playtime for Babies curriculum (Zero to Three, 2022 edition). Parents practiced supported sitting (on caregiver’s lap with lumbar support), tummy time progression (starting with 2-min intervals, increasing by 30 sec/day), and visual stimulation (high-contrast black-and-white cards held 25 cm from eyes — optimal focal distance for 4-week-olds).
Standardized screening tools were administered weekly:
- Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Screening Tool — administered at day 35: motor composite 88 (13th percentile), cognitive composite 94 (34th percentile), language composite 91 (22nd percentile)
- Parents’ Evaluation of Developmental Status (PEDS) — completed by mother: 1 concern flagged (“holds head up less than other babies”)
- Infant Behavioral Assessment and Reflection (IBAR) tool — nursing staff documented regulatory capacity: self-soothing attempts increased from 1 to 4 episodes/day across 7 days
These data informed goal-setting: “Maintain head control in upright position for 30 seconds unsupported by day 45” and “Initiate voluntary hand-to-mouth contact during alert periods.” Goals were shared electronically with Early Steps therapists via secure HIPAA-compliant portal (TherapyNotes®).
Family-Centered Care and Discharge Planning
Discharge occurred on day 38 after achieving all clinical milestones: bilirubin 8.9 mg/dL (stable for 24 hrs), weight 4.08 kg (+31.6% from birth), intake ≥70 mL/feed in ≤18 minutes, and RDOS score ≤2. Discharge planning prioritized continuity, safety, and parental competence.
We conducted three structured teach-back sessions using the Teach-Back Method (validated by AHRQ):
- Feeding: Mother demonstrated proper bottle angle, pace control, and recognition of satiety cues (turning head away, relaxed hands) with 100% accuracy
- Jaundice monitoring: Used BiliCheck® transcutaneous bilirubinometer (calibrated daily) to confirm trend downward; instructed to call if skin yellowing progresses cephalad past the umbilicus
- Developmental activity: Correctly performed 5 minutes of supported tummy time with rolled towel under chest and verbalized expected progression
Medications prescribed: None. Vitamin D supplementation continued at 400 IU/day (D-Vi-Sol®, 1 mL daily) per AAP recommendation. Follow-up scheduled for 48 hours post-discharge with pediatrician (Dr. Lena Patel, Bayfront Pediatrics), plus Early Steps home visit within 72 hours.
Community resources were activated pre-discharge: WIC enrollment confirmed (Hajeera qualified based on household income at 142% FPL); lactation consultant (IBCLC-certified, Karen Torres) scheduled for home visit on day 41; and transportation arranged via Medicaid Non-Emergency Medical Transportation (NEMT) for first follow-up.
Parental education materials included printed handouts from HealthyChildren.org (AAP) and customized feeding log templates (Excel-based, auto-calculating intake totals and weight velocity). We also provided access to the free, evidence-based app “BabySparks” (v4.2) — filtered for 1-month content only, with video demonstrations of neuroprotective positioning and oral-motor exercises.
Hajeera’s trajectory exemplifies how precise, physiologically attuned care transforms risk into resilience. Her bilirubin normalized without exchange transfusion. Her suck pressure increased by 35.7% in 8 days. Her weight velocity rose from 22.3 to 35.9 g/day — crossing the 90th percentile for weight gain velocity in the WHO growth standards. Most importantly, her mother reported reduced anxiety scores (GAD-7 from 10 to 3) and expressed confidence in recognizing subtle cues — the truest marker of successful transition from hospital to home.
This case underscores that hypotonia, jaundice, and respiratory variation are not isolated symptoms — they are interconnected expressions of neurodevelopmental maturation. Our role is not to pathologize variation, but to calibrate support to the infant’s unique biology and the family’s capacity. Hajeera’s progress was not accelerated by aggressive intervention, but by consistent, measurement-informed responsiveness — the hallmark of expert pediatric nursing.
For clinicians: Always measure, don’t estimate. Use validated tools — Ashworth, AIMS, RDOS, IIFS — not subjective impressions. For families: Trust your observations. A baby who feeds longer but gains weight steadily, breathes faster but maintains oxygen saturation, and moves less but tracks faces and smiles responsively is adapting — not failing. Growth charts, bilirubin logs, and feeding diaries are not bureaucratic hurdles; they are your child’s voice translated into actionable data.
Hajeera’s story continues beyond discharge. At her 2-month well-child visit, she achieved head control for 45 seconds, rolled from supine to side, and cooed responsively. Her Bayley-4 retest showed motor composite 94 (34th percentile) — a 6-point gain reflecting effective early intervention. Her bilirubin remained stable at 5.2 mg/dL. Her mother exclusively breastfed and returned to part-time work — supported by a flexible pumping schedule and employer-provided lactation space certified by the Business Case for Breastfeeding initiative.
Clinical vigilance remains essential. We monitor for emerging red flags: asymmetric tone, regression of milestones, conjugated bilirubin >1.5 mg/dL, or persistent tachypnea beyond 6 weeks. But for now, Hajeera thrives — not because she met arbitrary norms, but because her care was individualized, measured, and relentlessly human-centered.
As nurses, we do not wait for pathology to declare itself. We listen to the quiet signals — the slight pause before swallow, the extra second needed to lift the head, the subtle shift in respiratory rhythm — and respond before compensation fails. That is the essence of anticipatory, evidence-based infant care. Hajeera is not a diagnosis. She is a child whose biology, environment, and relationships converged to create a pathway forward — one carefully measured milliliter, millimeter, and minute at a time.
Her name means “the one who is patient and enduring” in Arabic — a fitting reflection of both her physiological journey and the sustained, attentive care that made her progress possible. In honoring that meaning, we honor the profound truth that every infant’s development unfolds on its own timeline — and our duty is to protect, support, and witness it with unwavering precision and compassion.
References embedded per AAP, WHO, and Cochrane standards include: American Academy of Pediatrics Clinical Practice Guideline: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation (2022); WHO Child Growth Standards (2006); Cochrane Database of Systematic Reviews: Oral-motor interventions for infants with feeding difficulties (2023); Bayley Scales of Infant and Toddler Development, Fourth Edition Administration Manual (2019).
